Dr. Rick Doblin, founder of MAPS (Multidisciplinary Association for Psychedelic Studies), discusses the current moment in psychedelic research and therapy — a field he has spent 40 years building from criminalization toward legal medical use. Psychedelics like MDMA, psilocybin, LSD, and ibogaine are showing profound results for PTSD, treatment-resistant depression, addiction, and anxiety, but the movement now faces a critical tension: whether these substances will be developed in a patient-centered way that includes therapy and integration, or whether for-profit pharmaceutical companies will strip away the therapeutic context to maximize repeat drug sales.
The Political and Historical Landscape
Psychedelics were criminalized in 1970 under the Controlled Substances Act, and Nixon’s war on drugs was explicitly political — John Ehrlichman later admitted the drug war targeted two enemies: the antiwar hippie movement and the criminal rights movement, by criminalizing the drugs associated with them.
Research was impossible worldwide until 1992, when the FDA — reshaped by ACT UP protests during the AIDS crisis demanding faster drug approval for life-threatening conditions — created the Pilot Drug Evaluation Staff, which opened the door to psychedelic research.
The opioid crisis was enabled by the same FDA loosening: OxyContin was approved through this streamlined process, and the FDA reviewer later went to work for Purdue Pharma. The resulting epidemic — over 100,000 annual overdose deaths at its peak — generated billions in settlement money to states, some of which is now being directed toward ibogaine research.
For the first time, Republicans have become champions of psychedelics, driven largely by veterans’ advocacy. Rick Perry (former Texas governor and Trump cabinet member) personally sought ibogaine treatment and helped secure $50 million from Texas for ibogaine research, with a potential $50 million federal match. An executive order from the Trump administration fast-tracked FDA review for several psychedelic compounds and expanded “right to try” access.
This bipartisan support was a deliberate strategy: Doblin took criticism for accepting $1 million from Rebecca Mercer (of Cambridge Analytica) for veteran-focused research, but Supreme Court Justice Stephen Breyer affirmed the approach: “The essence of democracy is trying to find common ground with people with whom you may disagree on everything else.”
How Psychedelics Work — Neuroplasticity and the Default Mode Network
Psychedelics open a “membrane” between conscious and unconscious mind, allowing suppressed traumatic memories, emotions, and formative experiences to surface. This is not recreational — it is a controlled therapeutic process.
The key mechanism is neuroplasticity: psychedelics mute the default mode network (the brain’s habitual self-referential processing), creating a window during which the brain can form new pathways and rewrite entrenched patterns of trauma, fear, and self-criticism.
Dr. Gül Dolan’s research at Johns Hopkins demonstrated this evolutionarily: when given MDMA, normally solitary octopuses became pro-social and spent time interacting with other octopuses. The pro-social effects of MDMA are conserved across species that diverged 600 million years ago.
The duration of the neuroplastic window varies by substance: MDMA’s lasts days, psilocybin’s longer, and ibogaine’s can last months — making the post-experience integration work critical.
Epigenetic mechanisms may also be affected: Rachel Yehuda’s research on Holocaust survivors showed trauma is passed epigenetically to children, and preliminary evidence suggests successful therapy (including MDMA therapy) can change these markers.
The Critical Importance of Therapy and Integration
The biggest threat to the field is for-profit companies trying to eliminate therapy — they want to sell the drug without the therapeutic context, because therapy doesn’t generate repeat revenue. Spravato (Johnson & Johnson’s ketamine nasal spray) is the model they aspire to: $2-3 billion in annual sales, no therapy required, effects lasting only 1-2 weeks, requiring repeated purchases.
Without therapy, neuroplasticity is wasted: the drug opens the brain’s window of possibility, but without skilled integration — processing traumatic memories, reframing experiences, building new coping patterns — people return to their baseline. As Doblin puts it, “When you don’t do therapy, you don’t take advantage of the neuroplasticity. People need to buy more of the drug. That’s what they want.”
Integration includes: dream work in the days following a session, body-based processing (Bessel van der Kolk’s “the body keeps the score”), therapeutic alliance (the single most important factor in psychotherapy outcomes), and ongoing non-drug work during the neuroplastic window.
Stanislav Grof’s insight: “The full expression of an emotion is the funeral of that emotion” — psychedelics help people feel emotions they’ve been defending against, and fully experiencing them (even terror, grief, ego dissolution) is what allows them to resolve.
Doblin’s personal ibogaine/LSD experience (1985): He spent 12 hours vomiting and resisting the experience, trapped in self-perfectionism and fear of death. Only after exhausting himself and surrendering did he have a breakthrough — realizing that self-criticism could be separated from self-hatred and made an ally. He was unable to move for another full day afterward.
Ibogaine — Unique Promise and Unique Risks
Ibogaine is the only psychedelic known to reset opiate dependence: after a single dose, people wake up without withdrawal symptoms. Howard Lotsof discovered this in the 1960s when he, a heroin addict, took ibogaine and lost his addiction.
The danger of the “reset”: if people relapse and use their previous dose, their tolerance has reset and they can overdose and die.
Ibogaine is the most physically dangerous psychedelic: it causes QT prolongation (a heart rhythm abnormality), and the FDA has placed a clinical hold on ibogaine studies because it exceeds their safety threshold. However, clinics in Mexico and New Zealand have administered it to thousands of patients under medical supervision (with magnesium and other cardiac support) with relatively few fatalities.
MAPS conducted two observational studies (in Mexico and New Zealand) showing promising results for addiction treatment using the Addiction Severity Index, with follow-up for one year.
Ibogaine is Schedule I in the US but legal or unregulated in most of the world — a consequence of American drug war overreach.
MDMA — From Therapy Drug to Party Drug and Back
MDMA was used therapeutically from ~1976-1985 under the name “Adam” before it escaped into recreational use as “Ecstasy.” The criminalization effort was triggered by the party use, not the therapy.
MDMA is the gentlest psychedelic but deeply profound — it reduces fear responses while increasing trust and emotional openness, making it ideal for PTSD. MAPS chose PTSD in veterans as a sympathetic patient population to build bipartisan support.
MAPS’ Phase 3 studies included veterans, firefighters, and police officers — the inclusion of police was both politically strategic and compassionate, given the trauma burden in law enforcement.
MDMA is not addictive in the traditional sense: developing tolerance leads to more amphetamine-like stimulation, not more openheartedness, so people don’t escalate doses the way they do with cocaine or alcohol.
MAPS Public Benefit Corporation was created to move MDMA through FDA approval with patient benefit prioritized over shareholder profit. However, after taking investors, MAPS lost control of the company (now called Resilient), and the new owners are pursuing a model that de-emphasizes therapy.
MDMA for couples therapy: MAPS is developing protocols for couples without clinical diagnoses, which challenges the FDA’s disease-only framework. The challenge is designing outcome measures — sometimes the healthiest outcome is separation.
The Current State of Research and Approval Pipeline
Nonprofits have raised ~$300 million; pharma investors have put in ~$6 billion into psychedelic research.
Compass Pathways (psilocybin for treatment-resistant depression) is likely to be first through FDA approval, potentially by the end of 2025. Other candidates include psilocybin for major depressive disorder, LSD for generalized anxiety disorder, 5-MeO-DMT for depression, and methylone (“MDMA-light”) for PTSD.
The executive order provides priority vouchers that reduce FDA review from 8+ months to 2-3 months, plus $50 million in federal research funding.
Doblin predicts 10,000 psychedelic clinics in America within 5-10 years, with therapists cross-trained in multiple substances and customizing treatments to individuals.
Transparency is critical: Doblin worries that political involvement will lead people to think approvals are politically motivated rather than scientifically earned. He advocates for all trial data and FDA communications to be public — as MAPS did — but no current company follows this practice.
Expanding Access — Churches, State Reform, and Peer Support
Hundreds of psychedelic churches now operate openly in the US, exploiting expanded religious freedom protections. The Church of Ambrosia in Oakland has 138,000 members and distributes ~100 pounds of mushrooms monthly as “offerings.” Some use plant medicines with indigenous roots; others use synthetics like LSD or MDMA.
State-level reforms: Oregon and Colorado have legalized psilocybin for adults without requiring a diagnosis — 18,000 people have received psilocybin in Oregon alone, more than all clinical study participants worldwide since 2000. MAPS is supporting a ballot initiative in Alaska for 2028.
MAPS’ Zeno Project provides psychedelic harm reduction at festivals and trains people in peer support — helping friends through difficult experiences rather than running from them.
Doblin envisions a “psychedelically literate population” with peer support networks, honest drug education (replacing DARE), and psychedelics used for prevention, spirituality, and connection — not just treating disease.
A licensing model (Timothy Leary’s idea) has been proposed: minimal education and a test to obtain a license to purchase psychedelics, which can be revoked for misuse — similar to how drunk driving can lead to license suspension.
Treating Younger Patients
There is growing momentum to treat people closer to the trauma, including adolescents. Yale has FDA permission to study psilocybin for OCD in 16-year-olds and is seeking approval for 14-year-olds. Harvard and UCLA are studying MDMA for PTSD in 18-to-22-year-olds with childhood trauma.
Doblin’s argument: traumatized brains are not developing normally anyway — layering in love, connection, and self-compassion early is beneficial, not harmful. Indigenous cultures (Native American Church, ayahuasca traditions) have no age limits for psychedelic use.
The counterargument: adolescent brains are still developing (until ~25), and there is limited data on how psychedelics interact with developing neurology. The hosts express concern about this and note the need for input from neurologists and developmental psychologists.
The Fundamental Tension — Capitalism vs. Altruism
MAPS was described as “walking the tightrope between capitalism and altruism.” The pharmaceutical industry’s incentive is to sell more drugs; the therapeutic model requires less drug use with more durable outcomes.
Public benefit corporations are a structural attempt to resolve this — prioritizing patient outcomes over profit maximization while still being financially viable.
The communities with the most trauma often have the least resources to pay for treatment. Insurance reimbursement systems favor drugs over therapy, and many therapists don’t take insurance. State-level reforms are not covered by insurance.
Doblin’s vision: a “gross national trauma measure” (analogous to Bhutan’s gross national happiness) to track humanity’s progress in reducing multigenerational trauma over the next 40 years — he is seeking a philanthropist to fund its development.
